Patent ID: 11884723
Assignee: OSE IMMUNOTHERAPEUTICS
Field: Pharmaceuticals (Chemistry)
Classification: CPC C  A  Y | IPC A  C

Claim 10:
11. A method of increasing the cross-presentation of an antigen by antigen presenting cells to T cells, said method comprising the administration to a SIRPa v1 positive subject a compound selected from the group consisting of an anti-human SIRPa antibody, an antigen-binding fragment thereof, and a modified antibody thereof, according to claim 1, said compound having at least the following properties:
i) it does not specifically bind to human SIRPa v2;
ii) it binds to human SIRPa v1 with an affinity of at least 1E−9 M;
iii) it decreases or inhibits the binding of human CD47 to human SIRPa v1; and
iv) it does not prevent or inhibit the binding of human CD47 to human SIRPg.